Phenomics Australia in partnership with Therapeutic Innovation Australia (TIA), Bioplatforms Australia (BPA), and ANSTO’s National Deuteration Facility (NDF), is thrilled to announce the successful recipients of the Pipeline Accelerator 2025-26 (Round 1).
Enabled by the National Collaborative Research Infrastructure Strategy (NCRIS), all four NCRIS providers mentioned above are working together to help address the medical products challenge outlined in the 2021 National Research Infrastructure (NRI) Roadmap.
Together, they provide academic researchers and SMEs seamless access to world-class Australian translational research infrastructure, from understanding the molecular basis of health and disease through to early-phase clinical trials.
In this round, 38 projects will share a total of $1,245,261 in voucher awards with a total cash co-investment fund of $1,495,763, facilitating access to national research infrastructure (NRI) to accelerate therapeutic translation and improve human health. These vouchers will subsidise the cost to access these translation NRIs to accelerate therapeutic translation and improve human health, supporting research in areas such as coronaviruses, encephalopathies, muscle atrophies, and paediatric disorders.
Eight recipients were awarded the Phenomics Australia Pipeline Accelerator 2025-26 (Round 1) and are listed below.
Among the recipients, we would like to highlight Dr Ryan Leung’s (Murdoch Children’s Research Institute) project on investigating the potential of differentiation therapy for paediatric diffuse hemispheric glioma. This project is jointly supported by the Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) and the Victorian Centre for Functional Genomics (PeterMac), both Phenomics Australia nodes.
We would also like to highlight Dr Thanh Nha Uyen Le (Hudson Institute of Medical Research). This project, a multi-omics strategy to reveal hidden genetic drivers in undiagnosed gonadal dysgenesis, is jointly supported by the Monash Genome Modification Platform (Monash Uni), a Phenomics Australia node and the Australian Genome Research Facility and Monash Proteomics & Metabolomics Platform, Bioplatforms Australia nodes.
Notably, several recipients are continuing their journey with us, a testament to its impact and value in advancing therapeutic research. For instance, Dr Kevin Watt from the Murdoch Children’s Research Institute has previously received support from us through our In Vivo services, highlighting the sustained value of these initiatives.
Phenomics Australia’s Pipeline Accelerator awards:
Click here to see the TIA voucher recipients.
The 8 recipients of the Phenomics Australia Pipeline Accelerator 2025-26 (Round 1) are listed below:
Click on the image to see the Phenomics Australia node involved
Dr Géza Berecki (Florey Institute of Neuroscience and Mental Health)
Phenomics Australia node: Monash Genome Modification Platform (Monash)
Developing an inducible mouse model of neonatal encephalopathy for preclinical evaluation of sodium channel modulators
Dr Jessica Neil (University of Melbourne)
Phenomics Australia node: Victorian Centre for Functional Genomics (PeterMac)
Development of a high-throughput lung epithelial cell screening platform for discovery of broadly-acting antivirals against coronaviruses
Dr Kevin Watt (Murdoch Children’s Research Institute)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Generation of a human stem cell model to screen for efficacy and potency of novel regenerative small molecules
Dr Laura Ellett (The Florey Institute of Neuroscience and Mental Health)
Phenomics Australia node: Monash Genome Modification Platform (Monash)
Generating a murine model of genetic prion disease relevant to Australian mutation carriers
Prof. Oliver Rackham (The Kids Research Institute Australia)
Phenomics Australia node: Monash Genome Modification Platform (Monash)
New preclinical models of mitochondrial disease
Dr Ryan Leung (Murdoch Children's Research Institute)
Phenomics Australia nodes: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Victorian Centre for Functional Genomics (PeterMac)
Investigating the potential of differentiation therapy for paediatric diffuse hemispheric glioma
Dr Thanh Nha Uyen Le (Hudson Institute of Medical Research)
Phenomics Australia node: Monash Genome Modification Platform (Monash)
Bioplatforms Australia node: Australian Genome Research Facility and
Monash Proteomics and Metabolomics Platform
A multi-omics strategy to reveal hidden genetic drivers in undiagnosed gonadal dysgenesis
Dr William Roman (Monash University)
Phenomics Australia node: Victorian Centre for Functional Genomics (PeterMac)
Genome-Scale Functional Screen to Discover Therapeutic Targets for Muscle Atrophy and Regeneration
Contact us to know more about this voucher scheme that aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.
Phenomics Australia, Bioplatforms Australia and TIA are members of NCRIS Health Group that works closely with each other and provide seamless access to world-class health and medical research infrastructure and expertise.
